Text Size: a  |   a 

How to Ease the Transition to a New RRMS Medication

March 28, 2018

With any chronic illness, from time to time one may have to switch medications. This could be due to symptoms worsening, or simply a lack of improvement in symptoms. Relapsing-remitting multiple sclerosis (RRMS) is normally treated with a class of drugs called disease-modifying therapies (DMTs). DMTs serve the purpose of slowing the rate of RRMS progression and disability, decreasing the number of RRMS “attacks” or relapses, and to stop new lesions from forming throughout the central nervous system.

Switching RRMS medications can be extremely difficult, use some of these tips to help ease the process.

Understand all of the changes that come with the new medication

Before switching DMTs, it is extremely important that you understand all of the new medication instructions and are willing to embrace an entirely new routine. You could have dosage changes that are completely different than what you are traditionally used to. Understand that the way in which you are given your DMT could also be different—some are given via infusion at a doctor’s office and others are taken orally or by injection at home.


In order to take the transition between medications a tad easier, really focus on self-care, comfort, and your overall well-being. Be mindful of the foods you are eating and make time for small forms of exercise, such as short daily walks. Be sure you are getting appropriate amounts of sleep and taking part in medication or yoga classes for the mental and emotional part of self-care—this will help you relieve any stress that could be building up. Make sure to also keep track of your pain—an often overlooked form of self-care. Note any triggers or patterns you notice in regards to your pain and let your doctor in on any of these observations.

Monitor your symptoms

Keep an eye out for any potential side effects from your new medications. Side effects can vary according to the individual, but they are still very much so a possibility. According to the National MS Society, 2 percent of users during clinical trials experienced all potential side effects.